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Abstract
Most clinical studies suggest that the prevalence and severity of liver steatosis are higher in patients infected with hepatitis
C virus (HCV) genotype 3 than in patients infected with other genotypes. This may reflect the diversity and specific intrinsic
properties of genotype 3 virus proteins. We analyzed the possible association of particular residues of the HCV core and
NS5A proteins known to dysregulate lipid metabolism with steatosis severity in the livers of patients chronically infected
with HCV. We used transmission electron microscopy to quantify liver steatosis precisely in a group of 27 patients, 12 of
whom were infected with a genotype 3 virus, the other 15 being infected with viruses of other genotypes. We determined
the area covered by lipid droplets in liver tissues and analyzed the diversity of the core and NS5A regions encoded by the
viral variants circulating in these patients. The area covered by lipid droplets did not differ significantly between patients
infected with genotype 3 viruses and those infected with other genotypes. The core and NS5A protein sequences of the
viral variants circulating in patients with mild or severe steatosis were evenly distributed throughout the phylogenic trees
established from all the collected sequences. Thus, individual host factors seem to play a much greater role than viral factors
in the development of severe steatosis in patients chronically infected with HCV, including those infected with genotype 3
viruses.
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Introduction
Hepatitis C virus (HCV), which infects 130 million people
worldwide, is a major cause of liver disease. It causes liver injury,
resulting in chronic hepatitis, fibrosis and, eventually, cirrhosis and
hepatocellular carcinoma (HCC). Progression towards end-stage
liver disease is influenced by several cofactors including sex
(progression more likely in men), age at infection, excessive alcohol
consumption, obesity and co-infection with hepatitis B virus (HBV)
or human immunodeficiency virus (HIV). Moreover, retrospective
studies have reported an association between the presence and
severity of steatosis in chronic HCV infection and advanced
fibrosis [1,2]. Steatosis is characterized by hepatic triglyceride
deposition and probably depends on host metabolic and viral
factors. HCV core protein deregulates a large number of genes
involved in lipid metabolism [3]. In cell culture, HCV core protein
associates with lipid droplets (LD) and induces the clustering of
these lipid storage organelles [4]. This LD clustering which plays
an important role in the viral life cycle could be due to a
subcellular redistribution of these organelles [5], but the
quantification of these clustered LD suggested that de novo LD
synthesis in infected cells was more likely [4]. The HCV NS5A
protein has also recently been shown to modulate various genes
involved in lipid metabolism [6,7], and to accumulate at the LD
surface in cell culture [8]. Nonetheless, the molecular mechanisms
underlying HCV-induced steatosis remain unclear. The HCV
RNA genome displays considerable diversity, both within and
between isolates, and three levels of classification have been
adopted, grouping viral sequences into six genotypes, several
dozen subtypes and intra-isolate variants [9]. Several clinical
studies have demonstrated that the prevalence and severity of
steatosis are higher in patients infected with genotype 3 HCV than
in patients infected with other genotypes [2,10–12], suggesting a
possible direct role for viral proteins in triggering steatosis.
However, conflicting conclusions have been drawn from in vitro
studies on the role of specific residues of the HCV-genotype 3 core
protein in steatosis [13–15]. Differences in the method of LD
quantification between studies may explain these discrepancies. In
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type or mutated HCV core proteins, we established an original
method for quantifying steatosis by transmission electron micros-
copy (TEM) [4,13]. We investigated the impact of HCV diversity
on steatosis severity, by applying this method to the analysis of
liver biopsy specimens from chronic HCV carriers with viruses of
genotype 3 or other genotypes. We aimed to quantify precisely the
accumulation of LD in liver tissues. We also determined the
sequence of the core and NS5A proteins of the viruses infecting
these patients, to evaluate the correlation between specific amino-
acid residues or motifs and steatosis severity.
Materials and Methods
Ethics Statement
All patients included in this study signed a written informed
consent form, in accordance with French regulations. This study
was approved by the Institutional Review Board of Tours
University Hospital (Comite ´ de Protection des Personnes - CPP).
Patients
HCV-infected patients meeting the following criteria were
recruited from two hospitals in the Loire Valley (Tours, Blois): (i)
known chronic HCV infection; (ii) never treated or with antiviral
treatment failure resulting in no further treatment for at least 11
months; (iii) known genotype of the infecting virus; (iv) age
between 18 and 75 years; (v) need for histological monitoring of
the liver, justifying liver biopsy. We excluded patients with
metabolic causes of steatosis, by applying the following exclusion
criteria: (i) presence of a metabolic syndrome, characterized by a
waist $94 cm (male)/$80 cm (female), and at least two of the
following criteria: triglyceride concentration .1.7 mmol/l or
treated for hypertriglyceridemia, HDL-cholesterol level
,1.03 mmol/l (male)/,1.29 mmol/l (female), systolic blood
pressure $130 mmHg/diastolic blood pressure $85 mmHg or
treated arterial hypertension, sugar concentration in a fasting
blood sample $5.6 mmol/l or treated diabetes; (ii) suspected
associated hepatic disease (Wilson’s diseases, alpha1-antitrypsin
deficiency, hemochromatosis, autoimmune hepatitis); (iii) alcohol
consumption .2 glasses/day; (iv) HIV or HBV coinfection; (v) ‘‘by
pass’’ gastrointestinal gastroplasty, parenteral nutrition, extensive
resection of the small intestine, intestinal bacterial overgrowth; (vi)
drug treatment potentially inducing or interfering with liver
steatosis.
Twenty-seven patients were included: 12 patients infected with
HCV genotype 3 and 15 patients infected with another genotype
(14 genotype 1 and 1 genotype 5). At the time of liver biopsy,
serum viral load (IU/ml) was determined, together with fasting
insulin and glucose concentrations, ALAT, ASAT, cGT and
alkaline phosphatase levels (IU/l).
Steatosis quantification in liver biopsy specimens
Liver biopsies were examined blind to patient information by a
pathologist (A.d.M), for routine histological diagnosis. A slice (at
least 15 mm) of each liver biopsy specimen was fixed in formalin
and embedded in paraffin. Sections were cut and stained with
hematoxylin-eosin-safran. Fibrosis and activity were graded on the
basis of METAVIR scores. For comparison with TEM results,
steatosis was also routinely graded 0 (0% hepatocytes with fat), 1
(,20% hepatocytes with fat), 2 (20–50% hepatocytes with fat), or 3
(.50% hepatocytes with fat). The remainder of each liver biopsy
specimen (at least 5 mm) was fixed and treated for standard TEM,
as previously described [4,13]. LD in ultrathin sections of these liver
biopsy specimens were quantified with a modified version of a
method originally developed for use in cultured cells [4,13]. TEM
grids were analyzed blind to patient information. LD diameter was
determined on the computer screen for five consecutive squares
(5000 mm
2 each) of two independent TEM grids (i.e. 10 different
areas of 5000 mm
2 of hepatic tissue, for each biopsy). LD diameter
was then converted into a disk area in mm
2. The areas covered by
the LD over which a TEM grid bar is partly superimposed were
determinedspecificallywith the ImageJprogram (NationalInstitute
of Health, USA). By summing these areas, we were able to
determine the cumulative LD area in mm
2 per TEM grid square.
For each biopsy, we summed the areas in the 10 squares analyzed.
Statistical analysis of the cumulative LD areas determined
by TEM
Samples from the patients were classified as infected with a
genotype 3 virus or with a virus of another genotype. The
differences between these groups were assessed with Fisher’s exact
tests for qualitative variables and Wilcoxon tests for quantitative
variables. Cumulative LD areas were compared between the two
groups, in a non parametric Wilcoxon test. The correlation
between the results obtained by TEM and routine histological
diagnosis was assessed by calculating Spearman’s rank correlation
coefficient with a 95% confidence interval. Data were analyzed
with SAS 9.2 and R software.
RNA extraction, cDNA synthesis, PCR amplification and
sequence analysis
RNA was extracted from 140 ml of serum with the QIAamp
Viral RNA Mini Kit (Qiagen) and stored at 280uC until
processing. For the amplification of core and NS5A coding
regions, RT-PCR was performed for 50 min with the Superscript
III First Strand Synthesis System (Invitrogen), with 8 ml of the
extracted RNA and 2 mM custom primers designed on the basis of
information from the HCV sequence database of the Los Alamos
National Laboratory (http://hcv.lanl.gov). Amplification was
performed with the Platinum PCR Supermix High-Fidelity
DNA polymerase (Invitrogen), by simple PCR (core region) or
nested PCR (NS5A region), with the custom primers and
hybridization temperatures reported in the supporting Table S1.
Five to 18 clones were generated per patient for each region
(mean: 9 for core and 13 for NS5A). Core and NS5A quasispecies
variant sequences were determined on an ABI PRISM 3100
machine (Applied Biosystems). BioEdit software (http://www.
mbio.ncsu.edu/) was used to compare amino-acid sequences.
Phylogenetic and molecular evolutionary analyses were conducted
with MEGA 5 software [16], by the maximum likelihood method.
Using the substitution rate for each amino acid over time, we
estimated the likelihood (bootstrap value .75%) of the position
and length of the branches of the tree. An evolutionary distance of
0.01 corresponded to 10 mutations per 1000 residues.
We specifically assessed the association of each individual
residue from all core and NS5A protein sequences with the
presence or absence of steatosis, using the Los Alamos – NCBI
Database(Highlightertool:http://hcv.lanl.gov/content/sequence/
HIGHLIGHT/highlighter.html) and CLC Main Workbench 6
software.
Results
General characteristics of patients at the time of liver
biopsy
Patients were assigned to one of the two groups on the basis of
viral genotype (3 or non-3). These two groups did not differ in
HCV Variability and Steatosis
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infection, alcohol intake, ALAT, ASAT and alkaline phosphatase
concentrations, glycemia, viral load or METAVIR score (Table 1).
However, patients with genotype 3 viruses had lower serum
cholesterol, TG and cGT concentrations than patients with viruses
of other genotypes. The difference in serum cholesterol concen-
tration between patients infected with genotype 3 viruses and those
infected with viruses of other genotypes has been reported
elsewhere [10,17], but the impact of HCV genotype on TG level
remains unclear. Our inclusion criteria were designed to exclude
patients with a metabolic syndrome, but we nevertheless carried
out homeostasis model assessment of insulin resistance (HOMA-
IR) [18] with the measurement of fasting insulin and glucose
concentrations at the time of liver biopsy. Median HOMA-IR
score was slightly higher in patients infected with non-3 genotypes,
but this difference was not significant (Table 1). However, four
patients with non genotype 3 viruses had a HOMA-IR score .4,
suggesting possible insulin resistance in these patients (Table 1).
Table 1. Demographic, biochemical and histological characteristics of the patients at the time of liver biopsy.
Genotype 3
a Genotype non 3 p-value
n=12 n=15
Male (%) 8 (66.7) 8 (53.3) NS
Ethnicity NS
European Caucasian 12 (100.0) 14 (93.3)
North-African Caucasian 0 (0.0) 1 (6.7)
Age (median) 49.0 [47.0; 50.5] 51.0 [48.0; 61.0] NS
BMI (median) 22.9 [21.2; 24.8] 24.7 [21.4; 26.1] NS
Duration of infection (median) 28.5 [20.5; 31.5]
b 29.0 [24.0; 31.0]
c NS
Source of infection (%) NS
Drug addiction 6 (50.0) 5 (33.3)
Transfusion 2 (16.7) 6 (40.0)
Other 2 (16.7) 2 (13.3)
Unknown 2 (16.7) 2 (13.3)
Alcohol intake (%) NS
0 glass/day 10 (83.3) 11 (73.3)
1–2 glass/day 2 (16.7) 4 (26.6)
Biochemical data (median)
ALAT (IU/l) 120.0 [49.5; 144.5] 79.0 [54.0; 111.0] NS
ASAT (IU/l) 71.0 [40.5; 92.5] 54.0 [40.0; 94.0] NS
GGT (IU/l) 71.5 [43.0; 103.5] 130.0 [99.0; 233.0] 0.012
Alkaline phosphatase 69.5 [61.0; 95.5] 81.0 [64.0; 108.0] NS
Total cholesterol (mmol/l) 3.9 [3.3; 4.0] 4.8 [4.4; 5.7] 0.0002
Glycemia (mmol/l) 5.0 [4.7; 5.6] 5.4 [4.8; 5.8] NS
Triglyceridemia (mmol/l) 0.74 [0.62; 1.13] 1.36 [1.14; 1.67]
d 0.004
HOMA-IR score (median) 1.40 [0.88; 2.51] 1.98 [1.36; 4.29]
d NS
Insulin resistance (HOMA-IR .4) (%) 0 (0.0) 4 (26.6) NS
Viral load (log IU/ml) 6.1 [5.8; 6.5] 6.2 [5.8; 6.6] NS
METAVIR Score (%) NS
A1F1 3 (25.0) 3 (20.0)
A1F2 1 (8.3) 1 (6.7)
A1F4 1 (8.3) 0 (0.0)
A2F1 2 (16.7) 3 (20.0)
A2F2 1 (8.3) 3 (20.0)
A2F3 3 (25.0) 3 (20.0)
A2F4 0 (0.0) 2 (13.3)
A3F4 1 (8.3) 0 (0.0)
aDetermined with the Versant HCV Genotype Assay.
bData missing for 4 patients.
cData missing for 2 patients.
dData missing for 1 patient.
doi:10.1371/journal.pone.0033749.t001
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The area covered by LD in 10 different areas of 5000 mm
2 of
hepatic tissue (50,000 mm
2 in total) was determined by TEM for
each liver biopsy specimen. Figure 1 shows LD on ultrathin
sections from the liver biopsy specimens of three different patients
with representative profiles. A box plot was generated for the
analysis of these cumulative LD areas as a function of viral
genotype (Fig. 2). Median cumulative LD area did not differ
significantly between the two groups (see the horizontal dark line
in each box): 5461.1[2165.2; 10027.9] for the genotype 3 group,
versus 3538.7[2184.6; 4984.4] for the genotype non-3 group
(p=0.581). However, the cumulative LD areas of patients infected
with genotype 3 viruses were much more variable than those of
patients infected with viruses of other genotypes (Fig. 2). The
quantification of LD by TEM was compared with the results of
steatosis assessment during routine histological analysis of the liver
biopsy specimen. With a Spearman’s rank correlation coefficient
of 0.87 [0.73; 0.94], histological steatosis grade was correlated with
the cumulative LD area obtained by TEM. The slight differences
observed may result from the detection, by TEM, of the
accumulation of small LD (microsteatosis) in some patients
considered free of steatosis in routine histological assessments.
All four patients infected with non genotype 3 viruses displaying
suspected insulin resistance (HOMA-IR .4 ; patients 7, 8, 15 and
18) had mild steatosis.
Analysis of HCV core and NS5A protein sequences as a
function of steatosis severity
We first investigated the involvement of HCV core and NS5A
protein residues in steatosis severity, in an analysis on a restricted
number of patients: those with severe liver steatosis, with an LD
area greater than 10,000 mm
2 on TEM (6 patients: 3 with a
genotype 3 virus, 2 with a genotype 1 virus and 1 with a genotype
5 virus); and those with very little or no steatosis, characterized by
an LD area less than 1,000 mm
2 on TEM (5 patients: 3 with a
genotype 1 virus and 2 with a genotype 3 virus). No association
was found between particular amino-acid residues or motifs
anywhere in the core region (domains 1, 2 and 3) and severe
steatosis (Supporting Fig. S1). For example, Figure 3 shows the
alignment of HCV core protein domains 2 (D2) and 3 (D3) of the
consensus sequence determined for the 11 patients. HCV core
protein D2 (residues 119–173) and D3 (residues 174–191) have
been implicated in the association of the protein with the surface of
the LD, and some key residues have been shown, in vitro,t o
increase LD accumulation in cultured cells [13,15]. Residues
highly specific to genotype 3 strains, such as the phenylalanine
residue in position 164, were found in all genotype 3 viruses, but
the presence of this particular residue was not associated with
steatosis severity (Fig. 3 and Supporting Fig. S1), despite the
previous implication of this residue in severe steatosis in vitro [13].
Similarly, the 182LI186 and 182FV186 motifs, which have also
been associated with higher levels of LD accumulation in in vitro
models [15], were not associated with severe steatosis in our
patients (Fig. 3). Indeed, only two patients were infected with
viruses bearing the 182LI186 or 182FV186 sequences (patients 26
and 27, Supporting Fig. S1), but only one of these patients had
severe steatosis. Patient 26 was the only one of the six patients with
severe steatosis found to be infected with a virus bearing the
182FV186 or 182LI186 sequence.
We then established a phylogenetic tree from the core protein
sequences of all variants found in all patients. The sequences
clustered by genotype (Fig. 4), with one group for genotype 1
sequences (14 patients), one group for genotype 3 sequences (12
patients) and an isolated sequence for genotype 5 (1 patient). Due
to the high degree of core sequence conservation within the
various genotypes, clones from the same patient did not necessarily
cluster, instead mixing with those from other patients. Thus,
clusters were found for only twelve patients, for whom diversity
within the various clones is indicated by the triangle at the top of
the branch. Patients with little or no (green) and severe (red)
steatosis were evenly distributed over this phylogenic tree, with no
particular cluster of the phylogenic tree associated with severe
steatosis.
The NS5A protein sequences of the variants in a given patient
were highly heterogeneous and we were unable to identify a
consensus sequence for most of the patients. We then constructed
phylogenetic trees with all these sequences. As for the core protein,
the distribution of variants between the three groups depended on
genotype (Fig. 5). NS5A protein sequences were highly heteroge-
neous and we were able to evaluate diversity for each patient
Figure 1. TEM observation of representative liver biopsy
specimens from three patients chronically infected with HCV.
The liver in A (patient P16) shows a small number of small LD (arrows)
and was found to have a lipid droplet area ,1000 mm
2 per 50,000 mm
2
of tissue. The liver in B (patient P20) has extremely large LD and was
found to have a LD area .10,000 mm
2 per 50,000 mm
2 of tissue. The
TEM photograph in C shows a high magnification of an individual
hepatocyte with several large LD, taken from a liver biopsy specimen
(patient P03) considered intermediate to the other two in terms of
steatosis severity. Scale bars: 20 mm in A and B; 2 mmi nC .
doi:10.1371/journal.pone.0033749.g001
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or no steatosis (green) and those with severe (red) steatosis were
again evenly distributed over the entire tree, indicating a lack of
association between any particular cluster of the phylogenic tree
and severe steatosis.
The binding of the core protein to NS5A has been shown to be
critical for virus particle assembly [19]. This interaction may
potentiate the effects of these proteins in lipid accumulation. We
therefore investigated whether any particular association of
residues between the core and NS5A sequences was correlated
Figure 2. Comparative analysis of the cumulative LD areas determined by TEM on liver biopsy specimens from patients infected
with genotype 3 viruses and viruses of other genotypes, in mm
2. Cumulative LD areas were summed for all patients with genotype 3
infection (left boxplot) and for patients infected with viruses of other genotypes (right boxplot). Boxplots show the median LD area (horizontal black
line), the 25
th and the 75
th percentile. Dot plots indicate the extreme values of cumulative LD area. There was no significant difference between the
two groups (5461.1[2165.2; 10027.9] for the genotype 3 group versus 3538.7[2184.6; 4984.4] for the non-3 group, p=0.581).
doi:10.1371/journal.pone.0033749.g002
Figure 3. Alignment of amino acids 119–191 of the core protein consensus sequences from 5 patients with little or no steatosis (in
green) and 6 patients with severe steatosis (in red). The 5 patients in with little or no steatosis had a LD area ,1000 mm
2 per 50,000 mm
2 of
liver tissue. The 6 patients with severe steatosis had a LD area .10,000 mm
2 per 50,000 mm
2 of tissue. Patients infected with genotype 3 strains are
indicated with an asterisk (*) and such patients are present in both groups. The residues at each position are indicated with the single-letter amino-
acid code. Amino acids identical to the first sequence are indicated by a dot. The positions of the residues shown in previous studies to increase LD
accumulation in vitro, in cultured cells, are indicated in red. No association was found between a particular amino-acid residue or motif and the
presence of severe steatosis.
doi:10.1371/journal.pone.0033749.g003
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from the core-NS5A fused sequences. For each patient, we fused
the most frequent HCV core sequence (highly conserved among
the variants for a given patient) with each of the NS5A variant
sequences. In this new analysis (Supplemental Fig. S2), the
branches of the phylogenic tree were positioned similarly to those
in the analysis of the NS5A protein alone, the sequences associated
with little or no steatosis (green) and those associated with severe
(red) steatosis being evenly distributed over the entire tree. This
suggests that there is no association between core and NS5A
residues to form particular clusters correlated with severe steatosis.
A serine cluster (serines in position 432, 434 and 437 in the
genotype 1a H77 sequence) in the C-terminal part of the NS5A
protein has been shown to be determinant for the NS5A-core
interaction [19]. We therefore focused particularly on these
residues in our variant sequences. However, this serine cluster in
position 432/434/437 was highly conserved in the NS5A
sequences from all variants in all patients (data not shown). We
then investigated the potential association of each individual
residue of the core and NS5A proteins with the presence or
absence of steatosis. We overcame the problem of genotype
specificity by first analyzing separately the patients infected with
genotype 1 viruses (n=14) and genotype 3 viruses (n=12). The
core and NS5A protein sequences of all variants were compared
with the NCBI consensus sequence for genotype 1 (supplemental
Fig. S3) or genotype 3 (supplemental Fig. S4) viruses. No residue
or group of residues was found to be associated with severe
steatosis, in either of the groups. However, this analysis led to the
identification of a residue in position 362 in the core-NS5A fused
sequences that was characteristic of the genotype 1 variants found
in patients with little or no steatosis (arrow in Fig. S3). We then
assigned the variant sequences from the 27 patients to three groups
(patients with little or no steatosis, patients with intermediate
steatosis, and patients with severe steatosis). Using CLC Main
Workbench 6 software, we determined, for each group, the most
frequent residue in each position and determined the percentage
conservation of these residues, focusing in particular on the residue
in position 362 (aa 171 in the NS5A protein of the H77 strain).
The D residue in 362 was highly conserved in all genotype 3
viruses, regardless of the presence or absence of steatosis (Fig. 6).
However, in the other genotypes, the D in position 362 was
characteristic of the variants found in patients with little or no
steatosis, whereas an E residue in position 362 was typically found
in the variants from patients with severe steatosis (Fig. 6).
However, the number of patients with non genotype 3 viruses
studied was too small to draw any firm conclusion about the role of
this residue in virus-induced steatosis.
Discussion
The mechanisms leading to liver steatosis in chronic hepatitis C
remain unclear, probably due to the existence of two different
entities: (i) steatosis with common causes, such as obesity, diabetes
mellitus or alcohol intake, (ii) steatosis without known risk factors,
presumably at least partly related to viral infection. Steatosis seems
to be mostly (but probably not exclusively) virus-induced in
infections with genotype 3 viruses, whereas it is principally
associated with host factors in infections with viruses of other
genotypes. We investigated this issue by an approach allowing the
precise quantification of steatosis in the liver tissues of patients
infected with viruses of genotype 3 and of other genotypes. This
study included only a small number of patients due to (i) inclusion
being limited to patients requiring histological monitoring of the
liver justifying liver biopsy, (ii) the difficulty of extending the
meticulous and time-consuming quantification of LD by TEM to a
large number of patients. In formalin-fixed tissues embedded in
paraffin for sectioning for routine histological diagnosis, the LD
fuse and tend to form holes, deformed to various extents [20], and
steatosis is evaluated by determining the percentage of hepatocytes
presenting this pattern. This routine evaluation of steatosis was
carried out for comparison with our original TEM method,
initially developed for a more precise quantification of steatosis in
liver biopsy fragments. This small number of patients may have
limited our analysis, but the main advantage of TEM was the
precise determination of LD area in liver tissues that it allowed,
including the quantification of small LD (microsteatosis) in some
parts of the tissue considered steatosis-free on routine histological
analysis. However, we are aware of the limitations associated with
the study of small fragments of biopsy specimens by TEM as
Figure 4. Unrooted phylogenic trees for the core protein
sequences of all variants identified in the 27 patients included
in the study. The 5 patients in green had a LD area ,1000 mm
2 per
50,000 mm
2 of liver tissue. The 6 patients in red had a LD area
.10,000 mm
2 per 50,000 mm
2 of tissue. The remaining 16 patients, with
steatosis of intermediate severity, are shown in black. Diversity in
individual patients is represented by a triangle at the top of the
branches, with the magnitude of the diversity observed increasing with
the area of the triange. Bootstrap values exceeding 75% are shown
(numbers in dark blue). Scale bars indicate evolutionary distance (0.01
indicates 10 mutations for every 1000 residues). Patients are grouped
according to viral genotype. Patients with little or no steatosis (green)
and those with severe (red) steatosis are evenly distributed over these
phylogenic trees. No clustering according to steatosis status was
observed.
doi:10.1371/journal.pone.0033749.g004
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overall correlation between the results obtained with the two
approaches was good. Using this original technique, we showed
that the cumulative area covered by LD in the livers of patients
infected with genotype 3 viruses did not differ significantly from
that in the livers of patients infected with viruses of other
genotypes. These results conflict with those of other studies
reporting a higher frequency of severe steatosis in patients infected
with genotype 3 viruses [2,10–12], but are consistent with several
studies showing this link to be non significant [21,22]. Serum
cholesterol concentration was lower in patients infected with
genotype 3 viruses than in patients infected with other genotypes,
Figure 5. Unrooted phylogenic trees for the NS5A protein sequences of all variants identified in the 27 patients included in the
study. The 5 patients in green had a LD area ,1000 mm
2 per 50,000 mm
2 of liver tissue. The 6 patients in red had a LD area .10,000 mm
2 per
50,000 mm
2 of tissue. The remaining 16 patients, with steatosis of intermediate severity, are shown in black. Diversity in individual patients is
represented by a triangle at the top of the branches, with the magnitude of the diversity observed increasing with the area of the triange. Bootstrap
values exceeding 75% are shown (numbers in dark blue). Scale bars indicate evolutionary distance (0.01 indicates 10 mutations for every 1000
residues). Patients are grouped according to viral genotype. Patients with little or no steatosis (green) and those with severe (red) steatosis are evenly
distributed over these phylogenic trees. No clustering according to steatosis status was observed.
doi:10.1371/journal.pone.0033749.g005
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could not be accounted for by the demographic profiles of the
patients. Lower serum cholesterol concentrations have been found
in patients infected with various HCV genotypes, probably due to
a global deficit in lipid and lipoprotein metabolism induced by
HCV that might be exacerbated in patients infected with genotype
3 viruses [23]. However, this lower serum cholesterol concentra-
tion in patients infected with genotype 3 viruses was not associated
with more severe steatosis in our study.
The mechanisms by which viral proteins affect the development
of genotype-3-specific steatosis remain hypothetical. The HCV
core protein accumulates at the surface of LD in vitro and in vivo,
induces steatosis in the livers of transgenic mice and deregulates a
large number of genes involved in lipid metabolism [3]. It has
therefore been extensively studied. Several in vitro studies have
shown a specific interaction between the genotype 3 core protein
and lipid metabolism. Early experiments based on the production
of HCV core proteins from viruses of different genotypes showed
that all core proteins induced triglyceride accumulation, but that
this phenomenon was strongest with genotype 3 core protein [24].
This protein strongly induces fatty acid synthase (FAS), an enzyme
required for intracellular triglyceride production, in a sterol
response element binding protein 1 (SREBP1)–dependent manner
[25]. HCV core protein induces the cleavage of sterol regulatory
element binding proteins and their phosphorylation, by triggering
oxidative stress, leading to fatty acid synthesis, this this
phenomenon is generally more efficient with a genotype 3 core
protein [26]. The phosphatase and tensin homolog (PTEN) has
recently been shown to be downregulated by a genotype 3 core
protein, via a mechanism involving a microRNA-dependent
blockade of PTEN mRNA translation, whereas genotype 1 core
protein has no effect [27]. The functional differences between
genotype 1 and 3 core proteins probably reflect differences in
amino-acid sequences, although these sequences are very similar.
However, single amino-acid differences between these proteins
may modulate local folds, stability and interactions with host cell
proteins. Core protein domain 2 (amino acids 119–173) has been
implicated in LD association [3,13]. Within this domain, the
Y164F mutation of a genotype 1 core protein, resulting in the
incorporation of a residue highly specific to genotype 3 strains, has
been shown to increase LD accumulation in vitro, in cellular models
[13]. This particular mutant has also been implicated in the
stronger FAS activation observed with the genotype 3 core protein
[25]. One group has also reported a possible link between
polymorphism in domain 3 (amino acids 174–191) of the genotype
3 core protein and steatosis [15,28]. The FV or LI combination of
residues at positions 182 and 186 in viral sequences (as opposed to
FI) has been reported to be associated with the presence of severe
intrahepatic steatosis in patients. The in vitro production of core
proteins with these steatosis-associated polymorphisms increases
intracellular lipid levels over those obtained with core proteins
from isolates not associated with steatosis [15,28]. However, the
presence of these particular residues was not correlated with severe
steatosis in our patients. We identified no particular amino-acid
residues or motifs associated with severe steatosis within core
sequences. Furthermore, careful phylogenic analysis of all the core
sequences collected showed an absence of sequence clustering as a
function of steatosis status. These results are consistent with those
of Piodi et al. [14], who found no difference between the genes
encoding genotype 3 virus core proteins between patients with and
without steatosis. However, as Piodi et al. showed that the genotype
3 core protein induced the formation of larger LD in vitro than the
Figure 6. Conservation of amino acids 161–181 of the NS5A protein sequences of all variants identified in the 27 patients included
in the study. The sequences were classified into three different groups : (i) patients with little or no steatosis, with a LD area ,1000 mm
2 per
50,000 mm
2 of liver tissue (n=5) ; (ii) patients with severe steatosis, with a LD area .10,000 mm
2 per 50,000 mm
2 of tissue (n=6) ; (iii) patients with a
steatosis of intermediate severity (n=16). Using CLC Main Workbench 6 software, we determined, for each group, the most frequent residue in each
position and the percentage conservation of these residues. The D in position 362 in the core-NS5A fused sequence (arrow, residue 171 in the NS5A
protein) was highly conserved in all genotype 3 viruses from all groups. For the other genotypes, the D on position 362/171 was characteristic of the
variants found in patients with little or no steatosis, whereas an E in the same position was characteristic of the variants found in patients with severe
steatosis.
doi:10.1371/journal.pone.0033749.g006
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diameter and area on liver biopsy specimens. Again, we found no
significant difference between genotype 3 and the other genotypes
(p=0.92; data not shown).
HCV NS5A protein colocalizes with the core protein on LD and
interacts with apolipoprotein (Apo) A1, ApoB and ApoE [8] and
with peroxisome proliferator-activated receptor gamma (PPAR-
gamma) [7]. Furthermore, the NS5A protein has recently been
shown to induce steatosis in a transgenic mouse model [6]. We
therefore analyzed the NS5A sequences of the multiple variants
circulating in our patients. The NS5A protein sequences of the
variants in a given patient were highly heterogeneous, and we were
therefore unable to identify a consensus sequence for most of the
patients for sequence alignment analysis. Phylogenic analysis of all
the N5A sequences collected showed no clustering according to
steatosis status. Finally, when analyzing NS5A sequence conserva-
tion by genotype, we showed that residue 171 of the NS5A protein
was potentially associated with steatosis status, but only in infections
with genotypes other than genotype 3 (D in patients with little or no
steatosis, E in patients with severe steatosis). However, these two
amino acids have similar properties and too few patients were
studied to draw any firm conclusions on the role of this specific
residue in the steatosis induced by non genotype 3 viruses.
Thus, our study suggests that core and NS5A protein variability
in HCV genotypes and strains has little effect on steatosis severity
in chronic HCV carriers. In particular, the effects of the genotype
3 core protein observed in vitro [13,15,24,25,27,28] seemed to be
much milder in vivo, in conditions in which host factors may have a
much stronger effect on steatosis severity. This is consistent with
the absence of a direct relationship in vivo between steatosis and the
presence of HCV proteins within steatotic hepatocytes [22].
Furthermore, the specific induction of higher SREBP1 levels by a
genotype 3 core protein in vitro [25] was not confirmed in a recent
analysis of gene expression in the livers of human patients infected
with HCV of various genotypes [29]. Our findings are consistent
with those of Piodi et al. [14], suggesting that host factors play a
greater role in the development of severe liver steatosis than viral
factors in patients infected with a genotype 3 virus, contrary to the
conclusions of the clinical studies previously addressing this
question. Interestingly, recent data have suggested that the
polymorphism of various genes, including the PPAR-gamma, IL-
28B, adiponutrin and microsomal triglyceride transfer protein
(MTP) genes, may influence the development of more severe
steatosis in chronic carriers of HCV [30–34]. An indirect factor,
such as alcohol consumption, which some patients might find it
difficult to acknowledge, may also have contributed to the
difference reported in previous studies between patients infected
with genotype 3 viruses and viruses of other genotypes. Indeed,
epidemiological studies in Western Europe, including France, have
shown that alcohol abuse is frequently observed in patients with a
history of intravenous drug use (IVDU) and that genotype 3
infection is frequent in patients with a history of IVDU [35].
In conclusion, our study suggests that individual host factors
seem to play a greater role than viral factors in the development of
severe steatosis in patients chronically infected with HCV,
including those infected with genotype 3 viruses.
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Figure S1 Alignment of the whole core protein consensus
sequences from the viruses identified in the 27 patients included
in the study. The 5 patients in green had a LD area ,1000 mm
2 per
50,000 mm
2 of liver tissue. The 6 patients in red had a LD area
.10,000 mm
2 per 50,000 mm
2 of tissue. The remaining 16 patients,
with steatosis of intermediate severity, are shown in black. Patients
infected with genotype 3 strains are indicated by an asterisk (*).
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Figure S2 Unrooted phylogenic trees for the core-NS5A fused
sequences of the variants identified in the 27 patients included in
the study. For each patient, we fused the most frequent HCV core
sequence (highly conserved among the variants for a given patient)
with each of the NS5A variant sequences. Patients with little or no
steatosis (green) and those with severe (red) steatosis are evenly
distributed over these phylogenic trees.
(EPS)
Figure S3 Comparison of the core-NS5A fused sequences of the
variants identified in the 14 patients infected with a genotype 1
virus with the NCBI consensus sequence for genotype 1. Patients
with little or no steatosis appear in green and patients with severe
steatosis appear in red.
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Figure S4 Comparison of the core-NS5A fused sequences of the
variants identified in the 12 patients infected with a genotype 3
virus with the NCBI consensus sequence for genotype 3. Patients
with little or no steatosis appear in green and patients with severe
steatosis appear in red.
(EPS)
Table S1 Sequences of the primers used and conditions for RT-
PCR amplification of the core and NS5A protein-coding regions.
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